You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,545,426

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,545,426 protect, and when does it expire?

Patent 9,545,426 protects BARHEMSYS and is included in one NDA.

This patent has fifty-two patent family members in twenty-six countries.

Summary for Patent: 9,545,426

Patent landscape, scope, and claims:

Title:	Use of amisulpride as an anti-emetic
Abstract:	Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Inventor(s):	Gilbert; Julian Clive (Cambridgeshire, GB), Gristwood; Robert William (Cambridge, GB), Cooper; Nicola (Essex, GB), Fox; Gabriel (Cambridgeshire, GB)
Assignee:	Acacia Pharma Limited (Cambridgeshire, GB)
Application Number:	14/812,148
Patent Claim Types: see list of patent claims	Use; Delivery;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,545,426

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acacia	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-001	Feb 26, 2020		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING	⤷ Subscribe
Acacia	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-001	Feb 26, 2020		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING	⤷ Subscribe
Acacia	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-002	Sep 1, 2020		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING	⤷ Subscribe
Acacia	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-002	Sep 1, 2020		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,545,426

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	1004020.2	Mar 11, 2010

International Family Members for US Patent 9,545,426

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011225898	⤷ Subscribe
Brazil	112012022746	⤷ Subscribe
Canada	2792392	⤷ Subscribe
China	102892407	⤷ Subscribe
Cyprus	1115485	⤷ Subscribe
Cyprus	1115487	⤷ Subscribe
Cyprus	1120170	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.